Skip to main content

Table 2 Associations between clinical determinants and reduced dietary intake

From: An evaluation of nutritional impact symptoms and their association with reduced dietary intake in patients with solid tumors at tertiary care hospitals: a multicenter, cross-sectional study from Palestine

Variables

Total (%)

n = 290

Reduced dietary intake

Yes

n = 215 (%)

Reduced dietary intake

No

n = 75 (%)

P value1

Univariate analysis

Multivariate analysis

(model 2)

     

Odds ratio with 95% CI

Odds ratio with 95% CI 4

Comorbid diseases

  

Hypertension

 Yes

 No

83 (28.6)

207 (71.4)

65 (30.2)

150 (69.8)

18 (24)

57 (76)

0.3042

1.372 (0.750–2.512)

Ref. (1)

 

Diabetes mellitus

 Yes

 No

69 (23.8)

221 (76.2)

50 (23.3)

165 (76.7)

19 (25.3)

56 (74.7)

0.7162

0.893 (0.486–1.642)

Ref. (1)

 

Type of solid cancer

  

Breast cancer

 Yes

 No

114 (39.3)

176 (60.7)

73 (34)

142 (66)

41 (54.7)

34 (45.3)

0.0022

2.346 (1.374–4.006)

Ref. (1)

0.885 (0.419–1.868)

Ref. (1)

Colorectal cancer

 Yes

 No

76 (26.2)

214 (73.8)

62 (28.8)

153 (71.2)

14 (18.7)

61 (81.3)

0.0852

0.566 (0.295–1.087)

Ref. (1)

 

Lung cancer

 Yes

 No

30 (10.3)

260 (89.7)

28 (13)

187 (87)

2 (2.7)

73 (97.3)

0.0063

0.183 (0.043–0.788)

Ref. (1)

2.306 (0.483–11.014)

Ref. (1)

Prostate cancer

 Yes

 No

14 (4.8)

276 (95.2)

12 (5.6)

203 (94.4)

2 (2.7)

73 (97.3)

0.2503

0.463 (0.101–2.120)

Ref. (1)

 

Uterus cancer

 Yes

 No

11 (3.8)

279 (96.2)

8 (3.7)

207 (96.3)

2 (2.7)

73 (97.3)

0.4983

0.709 (0.147–3.415)

Ref. (1)

 

Gastric cancer

 Yes

 No

9 (3.1)

281 (96.9)

8 (3.7)

207 (96.3)

1 (1.3)

74 (98.7)

0.2763

0.350 (0.043–2.843)

Ref. (1)

 

Bone cancer

 Yes

 No

9 (3.1)

281 (96.9)

6 (2.8)

209 (72.2)

3 (4)

72 (96)

0.4243

1.451 (0.354–5.954)

Ref. (1)

 

Ovarian cancer

 Yes

 No

8 (2.8)

282 (97.2)

5 (2.3)

210 (97.7)

3 (4)

72 (96)

0.3423

1.750 (0.408–7.507)

Ref. (1)

 

Others5

 Yes

 No

19 (6.6)

271 (93.4)

13 (6)

202 (94)

7 (9.3)

68 (90.7)

0.3332

0.625 (0.240–1.631)

Ref. (1)

 

Duration of cancer

 < 1 year

 1–5 year

 > 5 years

119 (41)

148 (51)

23 (7.9)

87 (40.5)

115 (53.5)

13 (6)

32 (42.7)

33 (44)

10 (13.3)

0.0922

Ref. (1)

1.282 (0.732–2.245)

0.478 (0.191–1.198)

 

Type of cancer treatments

  

Chemotherapy

 Yes

 No

222 (76.6)

68 (23.4)

180 (83.7)

35 (16.3)

42 (56)

33 (44)

< 0.0012

4.041 (2.257–7.233)

Ref. (1)

1.422 (0.642–3.146)

Ref. (1)

Biological treatment

 Yes

 No

69 (23.8)

221 (76.2)

42 (19.5)

173 (80.5)

27 (36)

48 (64)

0.0042

0.432 (0.242–0.771)

Ref. (1)

0.454 (0.234–0.880)

Ref. (1)

Hormonal treatment

 Yes

 No

45 (15.5)

245 (84.5)

21(9.8)

194 (90.2)

24 (32)

50 (66.7)

< 0.0012

0.216 (0.112–0.418)

Ref. (1)

0.340 (0.135–0.857)

Ref. (1)

Radiation therapy

 Yes

 No

9 (3.1)

281 (96.9)

7 (3.3)

208 (96.7)

2 (2.7)

73 (97.3)

0.5763

1.228 (0.250–6.047)

Ref. (1)

 

Surgery

 Yes

 No

24 (8.3)

266 (91.7)

13 (6)

202 (94)

11 (14.7)

64 (85.3)

0.0202

0.374 (0.160–0.877)

Ref. (1)

0.416 (0.156–1.108)

Ref. (1)

  1. 1 Bold values denote statistical significance at the level of p < 0.05
  2. 2Statistically significant differences were calculated using the chi-square test
  3. 3Statistical significance of differences calculated using Fisher’s exact test
  4. 4Bold values for odds ratios with 95% CIs denote statistical significance at the p < 0.05 level in the multivariate analysis model
  5. 5“brain tumor, endocrine, bladder, liver, kidney, and skin cancer”
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us